Dexamethasone Reduces Postoperative Emesis by Decreasing PGF2α and LTC4 Levels
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01811199
Recruitment Status : Unknown
Verified March 2013 by A.Ozdemir Aktan, Marmara University. Recruitment status was: Active, not recruiting
Hypothesis: Dexamethasone reduces postoperative emesis in thyroidectomy and mastectomy patients.
Condition or disease
Thyroid CancerBreast Cancer
This study has been done to further study the effectiveness of dexamethasone in the prevention of postoperative emesis after breast and thyroid surgery and at the same time, the mechanism of action was investigated. In this prospective, randomized controlled trial it was hypothesized that corticosteroids exert their antiemetic effects in postoperative period via plasma prostaglandin F2 alpha (PGF2 α) and plasma leukotriene C4 (LTC4) inhibition.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 65 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients undergoing thyroidectomy and mastectomy
breast and thyroid cancer patients no neoadjuvant treated no NSAID or steroid usage heallthy volunteers, signed the informed consent
ones who did not sign the consent form NSAID or steroid users